Cutaneous adverse reactions following <scp>SARS‐CoV</scp>‐2 vaccine booster dose: a real‐life multicentre experience

Avallone, Gianluca; Cavallo, Francesco; Astrua, Chiara; Caldarola, Giacomo; Conforti, Claudio; Simone, Clara De; Meo, Nicola di; Stefani, Alessandro; Genovese, Giovanni; Maronese, Carlo Alberto; Marzano, Angelo Valerio; Parente, Renato; Quaglino, Pietro; Roccuzzo, Gabriele; Tassone, F.; Zalaudek, Iris; Senetta, Rebecca; Ribero, Simone

doi:10.1111/jdv.18386

Cited by 22 publications

(27 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 Interestingly, and in line with our findings, cutaneous reactions to booster doses might happen even in the absence of reactions to the first and second shots. 1 , 2 The vaccine‐related PRP development may be induced by upregulation of inflammatory immunological pathways, or cross‐reactivity between viral or adjuvant molecules and self‐antigens. 1 , 8 It appears that in our patient, repeated exposure to the same mRNA vaccine stimulated the immune system, causing a cytokine imbalance that resulted in the development of PRP.…”

Section: Figuresupporting

confidence: 89%

“…However, data on cutaneous reactions following booster dose of COVID‐19 vaccines are still limited. 1 , 2 Herein, we present a case of pityriasis rubra pilaris (PRP) following a booster dose of the BNT163b2 (Pfizer–BioNTech) mRNA COVID‐19 vaccine.…”

Section: Figurementioning

confidence: 99%

“…Currently, cutaneous reactions following the booster dose represent only a small portion of the cutaneous reactions caused by COVID‐19 vaccines. 1 , 2 Nonetheless, as a result of booster vaccination having the potential to trigger immune‐mediated skin diseases, it is reasonable to expect more reports on vaccine‐induced cutaneous adverse reactions in the future. Finally, our case demonstrates the possibility of developing a cutaneous reaction after receiving a booster dose of mRNA COVID‐19 vaccine, even in the absence of a reaction to the first and second doses of the same SARS‐CoV‐2 vaccine.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Pityriasis rubra pilaris following booster dose of mRNA (Pfizer– BioNTech ) COVID ‐19 vaccine

Hlača

Žagar

Kaštelan

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Dear Editor, Data on various cutaneous adverse events as a result of widespread SARS-CoV-2 vaccination is currently accumulating. However, data on cutaneous reactions following booster dose of COVID-19 vaccines are still limited. 1,2 Herein, we present a case of pityriasis rubra pilaris (PRP) following a booster dose of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. An 85-years-old woman presented to our department with pruritic, erythematous lesions on her scalp, spreading to the trunk and palms, appearing one week after the injection of the booster dose of the Pfizer-BioNTech COVID-19 vaccine. By contrast, the patient reported only mild local tenderness after administration of the first and second dose of the Pfizer-BioNTech COVID-19 vaccine. The patient didn't reveal other possible triggers such as recent infections,changes in her medications, or exposure to UV light preceding the skin eruption. Her medical history was positive for chronic pancreatitis, arrhythmia, and arterial hypertension, and these conditions were well-controlled over a long period. She had no personal or family history of skin diseases. On physical examination, she presented with scaly orange to red plaques on her trunk and waxy yellow palmar keratoderma (Figure 1A-C). Her legs, soles, and nails were not affected

show abstract

Section: Figuresupporting

confidence: 89%

Section: Figurementioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Pityriasis rubra pilaris following booster dose of mRNA (Pfizer– BioNTech ) COVID ‐19 vaccine

Hlača

Žagar

Kaštelan

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Lymphocytic vasculitis is a histologic reaction pattern with a dominant lymphocytic inflammatory infiltrate ( 100 ). Reported cases of lymphocytic vasculitis followed the inoculation of Pfizer-BioNTech mRNA vaccine (BNT16B2b2) ( 101 ), Oxford-AstraZeneca adenoviral vaccine (ChAdOx1 nCoV-19 AZD1222) ( 102 ), inactivated vaccine Bharat Biotech Covaxin ( 103 ) and mRNA-1273 Moderna vaccine ( 104 ) ( Supplementary Table 4 ).…”

Section: Anti-sars-cov-2 Vaccination-induced Cutaneous Vasculitismentioning

confidence: 99%

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

Cutaneous vasculitides encompass a heterogeneous group of clinicopathological entities, which may occur as single-organ vasculitis of the skin or present as skin-limited variant of systemic vasculitis (i.e., skin-limited ANCA-associated vasculitis), and are triggered by various factors, including infections, drugs and vaccines. The COVID-19 pandemic has challenged us with a variety of both disease- and vaccine-associated skin manifestations, including vasculitis. Among the latter, cutaneous small-vessel vasculitis, previously known as leukocytoclastic vasculitis, seems to be the most reported in either scenario, i.e., natural infection and vaccination. Vasculopathy without true vasculitic changes on histology develops in but a minority of cases, mostly severe/critical COVID-19 patients, and appears to be the result of endothelial injury due to pauci-immune thromboembolic mechanisms. Herein, we provide an overview of the available literature on COVID-19-associated and anti-SARS-CoV-2-vaccine-associated cutaneous vasculitis. Although evidence is mostly limited to isolated reports, with a proportion of cases lacking histopathological confirmation, ample overlap with pre-pandemic forms is shown.

show abstract

“…Data on cutaneous reactions following booster dose for COVID‐19 derive only from a multicenter study and from the American Academy of Dermatology/International League of Dermatologic Societies registry. 4 , 5 Avallone et al reported their real‐life multicenter experience on 13 patients who experienced cutaneous reactions following booster dose of COVID‐19 vaccination. 5 In particular, 2 chilblain‐like, 2 urticaria, 2 pityriasis rosea‐like eruptions, 1 bullous pemphigoid, 1 herpes zoster, 1 maculo‐papular rash, 1 eczematous drug eruption, 1 lichenoid drug eruption, 1 erythema multiforme‐like, and 1 cutaneous vasculitis were described.…”

mentioning

confidence: 99%

Cutaneous reactions following booster dose of COVID‐19 mRNA vaccination: What we should know?

Potestio

Villani

Fabbrocini

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Cutaneous adverse reactions following SARS‐CoV‐2 vaccine booster dose: a real‐life multicentre experience

Cited by 22 publications

References 5 publications

Pityriasis rubra pilaris following booster dose of mRNA (Pfizer– BioNTech ) COVID ‐19 vaccine

Pityriasis rubra pilaris following booster dose of mRNA (Pfizer– BioNTech ) COVID ‐19 vaccine

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

Cutaneous reactions following booster dose of COVID‐19 mRNA vaccination: What we should know?

Contact Info

Product

Resources

About